Ligand Pharma (LGND) Tops Q1 EPS by 6c

Ligand Pharma (NASDAQ: LGND) reported Q1 EPS of $0.33, $0.06 better than the analyst estimate of $0.27. Revenue for the quarter came in at $14.6 million versus the consensus estimate of $13.5 million.

Ligand Pharma sees FY2015 EPS of $2.14-$2.18, versus the consensus of $2.13. Ligand Pharma sees FY2015 revenue of $81-83 million, versus the consensus of $82.3 million.

Ligand Pharma sees Q2 2015 EPS of $0.37-$0.40, versus the consensus of $0.35. Ligand Pharma sees Q2 2015 revenue of $17-17.5 million, versus the consensus of $16.4 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance